afriedman
Main Profile
- RUNX1
- C/EBPa
- NF-kB
Dr. Alan Friedman joins the Consortium from Johns Hopkins University where he is Professor of Oncology and Pediatrics. He received his M.D. from Harvard University and did his pediatric internship and residence at Boston Children’s Hospital. He then came to Johns Hopkins to complete a Fellowship in pediatric hematology/oncology. During that time he conducted post-doctoral research with Steven McKnight at the Carnegie Institute Department of Embryology before joining the Johns Hopkins Oncology Department faculty in 1989. He continues to care for pediatric oncology and transplant patients while devoting the majority of his time to research.
Dr. Alan Friedman (Johns Hopkins University) and Dr. John Cooke (Stanford University) will focus on the safe reprogramming and differentiation of adult cells to blood-forming cell lines for eventual application to blood or vascular disorders.
Dr. Friedman’s work focuses on mechanisms through which normal proteins control the formation of bone marrow stem cells and how these stem cells then develop into neutrophils and monocytes.
He is also studying how normal bone marrow cells become transformed into acute myeloid leukemia (AML). The focus is on three transcription factors:
Dr. Friedman is attempting to build on his basic research to develop useful clinical applications. In particular, in the context of the Consortium he is pursuing means to utilize RUNX1 and cooperating proteins to favor formation of adult HSC or neutrophils from hESC/iPSC for clinical application. In other work, he is seeking small molecules that interfere with the action of RUNX1 oncoproteins or interaction between C/EBP and NF-kB proteins as potential novel therapies for AML and other malignancies.
Copyright ©2013 NHLBI Progenitor Cell Biology Consortium.
